Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Abstract Text:

Naomi E Allen,Timothy J Key,Paul N Appleby,Ruth C Travis,Andrew W Roddam,Sabina Rinaldi,Lars Egevad,Sabine Rohrmann,Jakob Linseisen,Tobias Pischon,Heiner Boeing, Johnsen,Anne ,Henning ,Kim Overvad,Lambartus Kiemeney,H Bas Bueno-de-Mesquita,Sheila Bingham,Kay Tee Khaw,Rosario Tumino,Franco Berrino,Amalia Mattiello,Carlotta Sacerdote,Domenico Palli, ,Eva Ardanaz,Carmen Navarro,Nerea ,Carlos Gonzalez, Sanchez,Antonia Trichopoulou,Cryssoula Travezea,Dimitrios Trichopoulos,Mazda Jenab,Pietro Ferrari,Elio Riboli,Rudolf Kaaks,

BACKGROUND: Some studies suggest that elevated serum insulin-like growth factor (IGF)-I concentrations are associated with an increased risk of prostate cancer and, in particular, with an increased risk of advanced-stage prostate cancer. METHODS: We analyzed the association between prediagnostic serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. This study includes 630 incident prostate cancer cases and 630 matched control subjects. Odds ratios and their 95% confidence intervals (95% CI) were calculated for prostate cancer risk associated with increasing IGF-I and IGFBP-3 concentrations using conditional logistic regression. RESULTS: The risk of total prostate cancer in the highest versus the lowest third of serum peptide concentration was 1.35 (95% CI, 0.99-1.82; Ptrend = 0.08) for IGF-I, 1.39 (95% CI, 1.02-1.89; Ptrend = 0.12) for the IGF-I residuals after adjusting for IGFBP-3, 1.22 (95% CI, 0.92-1.64; Ptrend = 0.38) for IGFBP-3, and 1.01 (95% CI, 0.74-1.37; Ptrend = 0.75) for the IGFBP-3 residuals after adjusting for IGF-I. There was no significant difference in the association of peptide hormones and prostate cancer by stage of disease, although the association of serum IGF-I concentration with risk was slightly stronger for advanced-stage disease; the odds ratio for the highest versus the lowest third was 1.65 (95% CI, 0.88-3.08; Ptrend = 0.21) for IGF-I and 1.76 (95% CI, 0.92-3.40; Ptrend = 0.11) for IGF-I adjusted for IGFBP-3. CONCLUSIONS: In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease; no association for IGFBP-3 was observed.

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Publishing Authors By Initials

NE Allen,TJ Key,PN Appleby,RC Travis,AW Roddam,S Rinaldi,L Egevad,S Rohrmann,J Linseisen,T Pischon,H Boeing,NF Johnsen,A ,H ,K Overvad,L Kiemeney,HB Bueno-de-Mesquita,S Bingham,KT Khaw,R Tumino,F Berrino,A Mattiello,C Sacerdote,D Palli,JR ,E Ardanaz,C Navarro,N ,C Gonzalez,MJ Sanchez,A Trichopoulou,C Travezea,D Trichopoulos,M Jenab,P Ferrari,E Riboli,R Kaaks,

For similar investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research abstracts see: investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research

PUBMED ID PMID:

MEDLINE DATE:

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cancer epidemiology, biomarkers & prevention : a p

VOLUME: 16

Page Numbers: 1121-7

Journal Abbreviation: Cancer Epidemiol. Biomarkers P

ISSN: 1055-9965

DAY: 3

MONTH: Jun

YEAR: 2007

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9200608

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Keywords Mesh Terms:

KEYWORDS: Risk Factors

MESH TERMS: pathology

Chemical & Substance for Abstract: Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Information

Substance Name: Insulin-Like Growth Factor I

Registry Number: 67763-96-6

Grant and Affiliation Information for Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.

AFFILIATION: Cancer Research UK Epidemiology Unit, University of Oxford, Oxford OX3 7LF, United Kingdom. naomi.allen@ceu.ox.ac.uk

Country: United States

AGENCY: United Kingdom Wellcome T

GRANT: U01 CA098216-01

ACRONYM: CA

MEDLINETA: Cancer Epidemiol Biomarkers Pr

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Serum insulin-like growth factor IGF-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition Related Publications

• A potential inverse association between insulin-like growth factor I and hypertension in a cross-sectional study.
• IGF-I and mammographic density in four geographic locations: a pooled analysis.
• Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels.
• Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (
• Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition.
• Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.